2
|
Oliveira M, Sousa A, Sá S, Soares S, Pereira AC, Rocha AC, Pais P, Ferreira D, Almeida C, Luís C, Lima C, Almeida F, Gestoso Á, Duarte MC, Barata P, Martins-Mendes D, Baylina P, Pereira CF, Fernandes R. Harvesting the Power of Green Synthesis: Gold Nanoparticles Tailored for Prostate Cancer Therapy. Int J Mol Sci 2024; 25:2277. [PMID: 38396953 PMCID: PMC10889744 DOI: 10.3390/ijms25042277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Revised: 01/26/2024] [Accepted: 02/09/2024] [Indexed: 02/25/2024] Open
Abstract
Biosynthetic gold nanoparticles (bAuNPs) present a promising avenue for enhancing bio-compatibility and offering an economically and environmentally responsible alternative to traditional production methods, achieved through a reduction in the use of hazardous chemicals. While the potential of bAuNPs as anticancer agents has been explored, there is a limited body of research focusing on the crucial physicochemical conditions influencing bAuNP production. In this study, we aim to identify the optimal growth phase of Pseudomonas aeruginosa cultures that maximizes the redox potential and coordinates the formation of bAuNPs with increased efficiency. The investigation employs 2,6-dichlorophenolindophenol (DCIP) as a redox indicator. Simultaneously, we explore the impact of temperature, pH, and incubation duration on the biosynthesis of bAuNPs, with a specific emphasis on their potential application as antitumor agents. Characterization of the resulting bAuNPs is conducted using ATR-FT-IR, TEM, and UV-Vis spectroscopy. To gain insights into the anticancer potential of bAuNPs, an experimental model is employed, utilizing both non-neoplastic (HPEpiC) and neoplastic (PC3) epithelial cell lines. Notably, P. aeruginosa cultures at 9 h/OD600 = 1, combined with biosynthesis at pH 9.0 for 24 h at 58 °C, produce bAuNPs that exhibit smaller, more spherical, and less aggregated characteristics. Crucially, these nanoparticles demonstrate negligible effects on HPEpiC cells while significantly impacting PC3 cells, resulting in reduced viability, migration, and lower IL-6 levels. This research lays the groundwork for the development of more specialized, economical, and ecologically friendly treatment modalities.
Collapse
Affiliation(s)
- Marco Oliveira
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
| | - André Sousa
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FMUP, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
- FFCC-Facultad de Ciencias, University of Vigo, 36310 Vigo, Spain
| | - Sara Sá
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FMUP, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
- FFCC-Facultad de Ciencias, University of Vigo, 36310 Vigo, Spain
| | - Sílvia Soares
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FMUP, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
| | - Ana Cláudia Pereira
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
| | - Ana Catarina Rocha
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FMUP, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
| | - Patrick Pais
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- ECVA-UTAD, Escola de Ciências da Vida e do Ambiente, Universidade de Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal
| | - Diogo Ferreira
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FFCC-Facultad de Ciencias, University of Vigo, 36310 Vigo, Spain
- TBIO, Center for Translational Health and Medical Biotechnology Research, ESS-IPP, Escola S. Saúde, Instituto Politécnico do Porto, 4200-465 Porto, Portugal
| | - Cátia Almeida
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FMUP, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
| | - Carla Luís
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FMUP, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
| | - Cláudio Lima
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
| | - Fábio Almeida
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
| | - Álvaro Gestoso
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
| | - Miguel-Correa Duarte
- FFCC-Facultad de Ciencias, University of Vigo, 36310 Vigo, Spain
- CINBIO, University of Vigo, 36310 Vigo, Spain
- Southern Galicia Institute of Health Research (IISGS), Biomedical Research Networking Center for Mental Health (CIBERSAM), 36310 Madrid, Spain
| | - Pedro Barata
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FMUP, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
| | - Daniela Martins-Mendes
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- FMUP, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
| | - Pilar Baylina
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
- TBIO, Center for Translational Health and Medical Biotechnology Research, ESS-IPP, Escola S. Saúde, Instituto Politécnico do Porto, 4200-465 Porto, Portugal
| | - Carla F. Pereira
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
| | - Rúben Fernandes
- FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal
- CECLIN, Centro de Estudos Clínicos, Hospital Escola Fernando Pessoa, 4420-096 Gondomar, Portugal
- RISE-UFP, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- i3S, Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal
| |
Collapse
|
5
|
Cao P, Fleming D, Moustafa DA, Dolan SK, Szymanik KH, Redman WK, Ramos A, Diggle FL, Sullivan CS, Goldberg JB, Rumbaugh KP, Whiteley M. A Pseudomonas aeruginosa small RNA regulates chronic and acute infection. Nature 2023; 618:358-364. [PMID: 37225987 PMCID: PMC10247376 DOI: 10.1038/s41586-023-06111-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 04/21/2023] [Indexed: 05/26/2023]
Abstract
The ability to switch between different lifestyles allows bacterial pathogens to thrive in diverse ecological niches1,2. However, a molecular understanding of their lifestyle changes within the human host is lacking. Here, by directly examining bacterial gene expression in human-derived samples, we discover a gene that orchestrates the transition between chronic and acute infection in the opportunistic pathogen Pseudomonas aeruginosa. The expression level of this gene, here named sicX, is the highest of the P. aeruginosa genes expressed in human chronic wound and cystic fibrosis infections, but it is expressed at extremely low levels during standard laboratory growth. We show that sicX encodes a small RNA that is strongly induced by low-oxygen conditions and post-transcriptionally regulates anaerobic ubiquinone biosynthesis. Deletion of sicX causes P. aeruginosa to switch from a chronic to an acute lifestyle in multiple mammalian models of infection. Notably, sicX is also a biomarker for this chronic-to-acute transition, as it is the most downregulated gene when a chronic infection is dispersed to cause acute septicaemia. This work solves a decades-old question regarding the molecular basis underlying the chronic-to-acute switch in P. aeruginosa and suggests oxygen as a primary environmental driver of acute lethality.
Collapse
Affiliation(s)
- Pengbo Cao
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
- Emory-Children's Cystic Fibrosis Center, Atlanta, GA, USA
- Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA, USA
| | - Derek Fleming
- Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- Burn Center of Research Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Dina A Moustafa
- Emory-Children's Cystic Fibrosis Center, Atlanta, GA, USA
- Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, GA, USA
| | - Stephen K Dolan
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
- Emory-Children's Cystic Fibrosis Center, Atlanta, GA, USA
- Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA, USA
| | - Kayla H Szymanik
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA
| | - Whitni K Redman
- Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- Burn Center of Research Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- Department of Biological Sciences, Binghamton University, Binghamton, NY, USA
| | - Anayancy Ramos
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
- Emory-Children's Cystic Fibrosis Center, Atlanta, GA, USA
- Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA, USA
| | - Frances L Diggle
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
- Emory-Children's Cystic Fibrosis Center, Atlanta, GA, USA
- Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA, USA
| | | | - Joanna B Goldberg
- Emory-Children's Cystic Fibrosis Center, Atlanta, GA, USA
- Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, GA, USA
| | - Kendra P Rumbaugh
- Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- Burn Center of Research Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Marvin Whiteley
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
- Emory-Children's Cystic Fibrosis Center, Atlanta, GA, USA.
- Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA, USA.
| |
Collapse
|
6
|
Leggett A, Li DW, Bruschweiler-Li L, Sullivan A, Stoodley P, Brüschweiler R. Differential metabolism between biofilm and suspended Pseudomonas aeruginosa cultures in bovine synovial fluid by 2D NMR-based metabolomics. Sci Rep 2022; 12:17317. [PMID: 36243882 PMCID: PMC9569359 DOI: 10.1038/s41598-022-22127-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 10/10/2022] [Indexed: 01/10/2023] Open
Abstract
Total joint arthroplasty is a common surgical procedure resulting in improved quality of life; however, a leading cause of surgery failure is infection. Periprosthetic joint infections often involve biofilms, making treatment challenging. The metabolic state of pathogens in the joint space and mechanism of their tolerance to antibiotics and host defenses are not well understood. Thus, there is a critical need for increased understanding of the physiological state of pathogens in the joint space for development of improved treatment strategies toward better patient outcomes. Here, we present a quantitative, untargeted NMR-based metabolomics strategy for Pseudomonas aeruginosa suspended culture and biofilm phenotypes grown in bovine synovial fluid as a model system. Significant differences in metabolic pathways were found between the suspended culture and biofilm phenotypes including creatine, glutathione, alanine, and choline metabolism and the tricarboxylic acid cycle. We also identified 21 unique metabolites with the presence of P. aeruginosa in synovial fluid and one uniquely present with the biofilm phenotype in synovial fluid. If translatable in vivo, these unique metabolite and pathway differences have the potential for further development to serve as targets for P. aeruginosa and biofilm control in synovial fluid.
Collapse
Affiliation(s)
- Abigail Leggett
- Ohio State Biochemistry Program, The Ohio State University, Columbus, OH, USA
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA
| | - Da-Wei Li
- Campus Chemical Instrument Center, The Ohio State University, Columbus, OH, USA
| | - Lei Bruschweiler-Li
- Campus Chemical Instrument Center, The Ohio State University, Columbus, OH, USA
| | - Anne Sullivan
- College of Medicine, Wexner Medical Center, Columbus, OH, USA
- Department of Orthopaedics, The Ohio State University, Columbus, OH, USA
| | - Paul Stoodley
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
- Department of Orthopaedics, The Ohio State University, Columbus, OH, USA.
- Department of Microbiology, The Ohio State University, Columbus, OH, USA.
- National Biofilm Innovation Centre (NBIC) and National Centre for Advanced Tribology at Southampton (nCATS), Mechanical Engineering, University of Southampton, Southampton, UK.
| | - Rafael Brüschweiler
- Ohio State Biochemistry Program, The Ohio State University, Columbus, OH, USA.
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.
- Campus Chemical Instrument Center, The Ohio State University, Columbus, OH, USA.
- Department of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH, USA.
| |
Collapse
|